Cross-Sectional Associations of Visfatin and YKL-40 With Carotid Intima-Media Thickness in Peritoneal Dialysis: A 12-Month Prospective Cohort Study
Therapeutic Apheresis and Dialysis, 2026 (SCI-Expanded, Scopus)
- Yayın Türü: Makale / Tam Makale
- Basım Tarihi: 2026
- Doi Numarası: 10.1002/1744-9987.70221
- Dergi Adı: Therapeutic Apheresis and Dialysis
- Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, EMBASE, MEDLINE
- Anahtar Kelimeler: adiponectin, carotid intima-media thickness, peritoneal dialysis, visfatin, YKL-40
- Ankara Üniversitesi Adresli: Evet
Özet
Background: Cardiovascular disease is the leading cause of mortality in peritoneal dialysis (PD) patients. We investigated the cross-sectional and longitudinal associations of visfatin, YKL-40, and adiponectin with carotid intima-media thickness (CIMT) over 12 months. Methods: In this 12-month prospective cohort study, 30 maintenance PD patients underwent serial serum biomarker assessment and bilateral CIMT measurement. Associations were evaluated using paired comparisons and correlation analyses. Results: Both right and left CIMT increased significantly over 12 months (p < 0.01). Visfatin increased, adiponectin decreased (both p < 0.001), whereas YKL-40 remained stable. Visfatin and YKL-40 showed significant positive correlations with CIMT, while adiponectin showed negative correlations. A strong positive visfatin–YKL-40 inter-correlation was observed (r = 0.659, p < 0.001), representing a novel finding, to our knowledge, in a dialysis population. Conclusions: CIMT increased significantly over 12 months in PD patients. Visfatin and YKL-40 showed consistent positive cross-sectional associations with CIMT, whereas adiponectin showed inverse associations and declined over time. Longitudinal biomarker-CIMT associations were limited, with baseline YKL-40 being the only biomarker associated with right-sided ΔCIMT. These exploratory findings suggest potential inflammatory pathways involved in vascular remodeling in PD and warrant validation in larger prospective studies.